ArticleMucosal immunology2021

CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.

Pedram Shafiei-Jahani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.